Our vision is to improve the treatment of severe diseases in order to provide benefits for both patients and society as a whole.
Capital Markets Day
On June 15th, Oasmia Pharmaceutical AB held a Capital Markets Day in Stockholm.
Oasmia in brief
Our vision is to improve the quality for treatment of severe diseases. Researching and developing next generation medicines, our focus is on advancing oncology treatments.
At Oasmia, we’re developing the next generation of drugs with focus on oncology.
At our EMA and FDA-approved production facility we manufacture drugs for both clinical trials and sales.
Our nanoparticle platform XR17 possesses unique properties to improve current and future medicines.